1 Min Read
Jan 29 (Reuters) - Botanix Pharmaceuticals Ltd:
* PHASE 1B STUDY OF BTX 1503 IN PATIENTS WITH MODERATE TO SEVERE ACNE MET ALL DESIGNATED ENDPOINTS Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.